Annovis Bio (ANVS) said Wednesday it enrolled the first two participants in its phase 3 trial of buntanetap for early Alzheimer's disease.
The trial will evaluate the safety and efficacy of a daily dose of buntanetap, with treatment lasting for 18 months.
The study includes a 6-month assessment of symptomatic effects followed by a 12-month evaluation of potential disease-modifying effects. Annovis said it plans to enroll more than 750 patients across about 100 sites in the US.
The US Food and Drug Administration approved the Phase 3 protocol for the trial in January, the company added.
Shares of Annovis were down 1.4% in recent trading.
Price: 3.10, Change: -0.04, Percent Change: -1.43
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。